Two meningioma cell lines, IOMM-Lee and CH-157 MN, harbor the C228T hotspot TERT promoter mutation and could be useful to develop and test TERT inhibitors given their current lack of clinical testing [42]. This evidence concerns the gene TERT and meningioma.